Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratio per 1 s.d. of the risk score (~6 alleles) (95% confidence interval) = 1.24 (1.20-1.27), P = 5.05 × 10 −49 ), and we observed a 3.7-fold difference in COPD risk between individuals in the highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in genes for development, elastic fibers and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications.
Maximally attained lung function and subsequent decline in lung function together determine the risk of developing COPD 1, 2 . COPD, characterized by irreversible airflow obstruction and chronic airway inflammation, is the third leading cause of death globally 3 . Smoking is the primary risk factor for COPD, but not all smokers develop COPD and more than 25% of COPD cases occur in never smokers 4 . Patients with COPD exhibit variable presentation of symptoms and pathology, with or without exacerbations, with variable amounts of emphysema and with differing rates of progression. Although risk factors for COPD are known, including smoking and environmental exposures in early 5, 6 and later life, the causal mechanisms are not well understood 7 . Disease-modifying treatments for COPD are required 7 .
Understanding genetic factors associated with reduced lung function and COPD susceptibility could inform drug target identification, risk prediction, and stratified prevention or treatment. Previous genome-wide association studies (GWAS) of COPD identified several independent COPD-associated variants [8] [9] [10] , but the rate and scale of discovery have been limited by available sample sizes. We conducted a GWAS for lung function and followed up robustly associated variants in COPD case-control studies. Although previous GWAS have reported genome-wide significant associations with lung function [11] [12] [13] [14] [15] [16] , there has not been a comprehensive study confirming the effect of these variants on COPD susceptibility. In this study, we hypothesized that (i) GWAS of lung function with high power and large scale would detect novel loci associated with quantitative measures of lung function; (ii) collectively, these variants would be associated with risk of developing COPD; and (iii) aggregate analyses of all new and previously reported signals of association, and the identification of genes through which their effects are mediated, would give further insight into biological mechanisms underlying the associations. Together, these findings could provide potential novel targets 17 for therapeutic Table 5 ); 13 of these signals were fine-mapped to ≤10 plausible causal variants and, for 63 of the 67 signals fine-mapped, the sentinel variant (with the lowest P value) was also the top ranked variant by posterior probability. In addition, by refining six chromosome 6 major histocompatibility complex (MHC) association signals using imputation of classical alleles and amino acid changes (Online Methods), we identified an amino acid change at position 57 of the MHC class II HLA-DQB1 gene product HLA-DQβ1 (alanine as compared to nonalanine) as the main driver of signals in the MHC region for both We found that 29 of the lung-function-associated signals had previously shown genome-wide significant associations in GWAS of traits other than lung function or COPD. These traits included inflammatory bowel disease (Crohn's disease and/or ulcerative colitis; three signals) and height (nine signals, three of which showed a consistent direction of effect on height and the lung function measure with which they were most strongly associated) (Supplementary Table 7) . With the exception of KANSL1 (ref. 16) , there was no significant (P < 5.15 × 10 −4 ) association with smoking for any of the signals (Supplementary Table 8 ).
Ninety-five variants and COPD susceptibility
The disease relevance of lung-function-associated variants has been questioned 21 . Therefore, we tested association with COPD susceptibility for variants representing 95 of the 97 lung-function-associated signals in up to 20,086 COPD cases and 215,630 controls (data were unavailable for further study for the X-chromosome variant rs7050036[A>T] near AP1S2 and a rare variant, chr12:114743533[C>T]) (Supplementary Table 9 ). These cases and controls made up the COPD study at deCODE Genetics 22 (COPD cases defined using spirometry data, population-based controls excluding known cases, up to 1,964 moderate-to-severe cases, up to 142,262 controls), three lung resection cohorts [23] [24] [25] (COPD definition based on spirometry data, 310 moderate-to-severe cases, 332 controls), four case-control studies employing post-bronchodilator spirometry [8] [9] [10] [26] [27] [28] [29] ( Where the discovery variant was not available in replication cohorts but a proxy with r 2 >0.8 was available, the proxy was used for replication in all cohorts (proxies are marked with an asterisk in the rsID column). For discovery, the standard errors and P values are genomic controlled except for conditional analyses (the SNP conditioned on is given in parentheses in the rsID column), where unadjusted standard errors and P values are given. Genomic-controlled results were used for SpiroMeta. Unadjusted results were used for UK Biobank or UKHLS where genome-wide inflation factors were not available. Values are missing from stage 2 studies where there was quality control failure due to poor imputation (info <0.5) or low minor allele count (MAC <3). In the meta-analysis of the stage 2 replication cohorts, the P values for the 39 variants showing independent replication (Bonferroni correction for 81 tests, P < 6.17 × 10 −4 ) appear in bold. The "Nearest gene(s)" column lists either the location of the marker within the gene or, for intergenic markers, the nearest genes on each side of the marker. Stage 1 association results (FEV cases, 27,387 controls). UK BiLEVE COPD cases and controls were only used for single-variant COPD association tests for the subset of 47 variants discovered independently of UK BiLEVE (that is, excluding the 43 variants discovered using the UK BiLEVE data described in this paper and 5 variants reported in our previous study in the UK BiLEVE population 16 ). Across all 95 variants, 51 showed nominal COPD association (P < 0.05) and 30 showed association with COPD susceptibility reaching a Bonferroni-corrected threshold for 95 tests (P < 5.26 × 10 −4 ; Supplementary Table 10) . Of these 30 variants, 27 were variants discovered independently of UK BiLEVE and 3 were from the 48 lower-powered association tests not including UK BiLEVE cases and controls. Using a risk score based on the available 95 sentinel variants or their best proxies, and using data from up to 9,791 COPD cases and 120,462 controls (Online Methods), for the meta-analysis the odds ratio (OR) (95% confidence interval (CI)) per 1 s.d. change in risk score (~6 alleles) was 1.24 (1.20-1.27), P = 5.05 × 10 −49 ( Fig. 2a and Supplementary Table 11 ). We observed considerable heterogeneity in effect estimates among the different COPD studies (I 2 = 92%), which had different approaches to ascertainment of COPD cases and variable disease severity. In UK Biobank (including UK BiLEVE), we found broadly similar effect size estimates for moderate-to-severe COPD to those found in COPD case-control studies employing postbronchodilator spirometry (OR = 1.42 versus 1.36, respectively), and we therefore undertook further modeling showing a gradation in susceptibility to moderate-to-severe COPD across deciles of allelic risk score (Online Methods). The risk for moderate-to-severe COPD was more than three times higher in the top decile than it was in the bottom decile (OR = 3.71, 95% CI = 3.34-4.12; Fig. 2b ). The estimated proportion of COPD cases attributable to allelic risk scores above the first decile (population attributable risk fraction) was 48.0% (95% CI = 43.6-52.2%).
We tested association of individual variants and the 95-variant risk score with COPD exacerbations in subsets of individuals from UK Biobank, deCODE, four COPD case-control studies and two eMR studies (total of 2,462 COPD exacerbation cases and 15,288 COPD non-exacerbation controls) and the Lung Health Study (100 exacerbation cases and 4,002 controls). There was no association of individual variants or genetic risk score with acute exacerbations of COPD (Supplementary Tables 12 and 13) .
To evaluate whether these variants showed disease-relevant associations in a non-European population, we studied 71 variants for which data were available in 7,116 COPD cases (20,919 controls) and 5,292 exacerbation cases (1,824 controls) from the China Kadoorie Biobank (CKB) cohort (Supplementary Tables 10-13 ). The allelic risk score was associated with COPD susceptibility (OR per 1 s.d. change in risk score (95% CI) = 1.08 (1.04-1.11), P = 4.2 × 10 −6 ), suggesting some shared genetic contributions to COPD in populations of European and East Asian descent. Thirty-nine of the variants showed a consistent direction of effect on COPD in European and Chinese samples, and seven of these were significant (P < 0.05). Two signals were significant after correction for multiple testing (Supplementary Table 10c) .
To assess the impact of including individuals with asthma in a COPD case-control analysis, we tested for association with COPD in UK Biobank both before and after excluding individuals with self-reported doctor-diagnosed asthma and show that the effect size estimates were similar (Supplementary Fig. 7) . FEV 
Implicated genes highlight pathways and druggable targets
Gene expression and genotype data from lung, blood and multi-tissue resources were queried to determine whether the top variant at each of the 97 signals, or a proxy, was significantly associated with changes in expression of any gene (was an expression quantitative trait locus (eQTL) for any gene). Using this approach and identification of deleterious variants within the association signal (Online Methods and Supplementary Table 14) , we identified 234 genes with potentially causal effects on lung function (Supplementary Table 15 ). These 234 genes were enriched (false discovery rate (FDR) ≤5%) in elastic fiber pathways and in 'signaling events mediated by the Hedgehog family' , with the latter including CDON, which was implicated by a new intergenic signal (rs567508; between CDON and RPUSD4) on chromosome 11. We narrowed this group of 234 genes to 68 'highpriority genes' that were implicated via a deleterious variant or on stricter criteria for colocalization with a gene expression signal (r 2 ≥ 0.9 between the sentinel variant and top expression-associated variant; Table 2 ). We found that the 68 high-priority genes were over-represented (FDR ≤ 5%) among a number of gene ontology terms, including SH3 domain binding, GTPase binding, actin binding and fibroblast migration (Supplementary Table 16 ). Alternative approaches to pathway analyses, which instead use all genome-wide association results, supported previous reports of enrichment of histone and systemic lupus erythematosus pathways [14] [15] [16] and additional autoimmune and inflammatory pathways (Supplementary Table 17 ). Tests for tissuespecific enrichment of lung function signals overlapping histone marks identified enrichment in fetal lung, fetal heart and fibroblasts (H3K4me1) and stomach smooth muscle (H3K4me1 and H3K4me3) (Supplementary Table 18 ). Approved drugs, or drugs in development, target the protein products of 7 of the 234 genes (Supplementary Table 19a ). This includes three high-priority genes-CHRM3, SLC6A4 and CRHR1. CHRM3 and SLC6A4 were both implicated by new signals (rs6688537 [C>A] in an intron of CHRM3 and rs59835752[-/A] in an intron of EFCAB5, respectively) and encode targets for drugs approved for the treatment of asthma and COPD (CHRM3, muscarinic acetylcholine receptor M3) and anxiety and depression (SLC6A4, serotonin transporter). CRHR1 (implicated by rs35524223[T >A] in an intron of KANSL1) encodes corticotropin-releasing factor receptor 1, which is a target for compounds in development for the treatment of anxiety, depression and irritable bowel syndrome. The other four genes include NDUFA12 (implicated by rs113745635 [C>T] in an intron of FGD6) encoding an NADH dehydrogenase that is a target for metformin hydrochloride, primarily used to treat type 2 diabetes, and ITK (implicated by rs10515750 in an intron of CYFIP2) encoding a tyrosine protein kinase, a target for the cancer drug pazopanib.
Using STRING 31 to find proteins that interact with the proteins encoded by the high-priority genes, we highlighted further druggable targets (Supplementary Table 19b) . These included the phosphoinositol 3-kinase p110-delta subunit (part of the inositol phosphate metabolism pathway with INPP5E, which was implicated as a highpriority gene by rs10870202 in an intron of DNLZ, and a target for compounds in development for the treatment of COPD and asthma) and matrix metalloproteinases 1, 7 and 8 (targets for doxycycline, which is an antibiotic and antimalarial).
DISCUSSION
In this study, the power gained by sampling from the extremes of a large biobank while retaining the power of a quantitative trait analysis, coupled with strategies to improve coverage of the genome and extensive follow-up, enabled a near-doubling of the number of signals of association with lung function identified thus far. We further explored 95 variants, representing 43 new signals and 52 previously reported signals, and we showed that collectively these variants are strongly associated with COPD susceptibility.
Using functional evidence from eQTL studies and deleterious variants to link signals to genes, we found that 41 of the 97 lung function signals are also the strongest signals of association for expression of, or contain deleterious variants within, 68 genes (which we term 'high-priority genes'). Among these, new signals in or near FAM13A and ADAM19, both previously associated with lung function and "eMR", electronic medical records study using ICD codes to define COPD (DiscovEHR also used spirometry data to refine the COPD definition); "case-control", COPD case-control study using post-bronchodilator spirometry data to define COPD; "lung resection cohort", study using a combination of pre-and post-bronchodilator spirometry data to define COPD; Icelandic Biobank (deCODE), cohort where cases were selected from a population-based study and a study of patients with COPD using a spirometric definition and controls were selected as individuals within the cohort who were not known cases (no spirometric definition was used for controls); and UK Biobank (excluding UK BiLEVE), cohort where spirometry data were used to define both COPD cases and controls. Further details are provided in the supplementary Note. (b) Odds ratios (bars, 95% CI) for spirometrically defined COPD from weighted genetic risk score deciles in UK Biobank (10,547 cases (pre-bronchodilator percent predicted FEV 1 <80% and FEV 1 /FVC <0.7) and 53,948 controls (FEV 1 /FVC >0.7 and percent predicted FEV 1 >80%); weights were derived from non-discovery populations). For each decile, odds ratios were obtained using logistic regression adjusted for age, age 2 , sex, height, smoking status, pack-years and the first ten ancestry principal components. The odds ratio for comparison of the 10th and 1st deciles in ever smokers only was 3.35 (95% CI = 2.93-3.84) and in never smokers only was 4.27 (95% CI = 3.61-5.06).
COPD susceptibility 9, 32 , along with evidence that these signals are themselves eQTLs for FAM13A and ADAM19, provide further evidence for FAM13A and ADAM19 themselves being the drivers of those signals. There was significant enrichment amongst the 68 genes for SH3 domain (including ADAM19), GTPase and actin binding, and fibroblast migration, highlighting the potential importance of pathways relating to the cytoskeleton.
The 68 genes identified as high priority included genes at new signals encoding targets for which there are approved drugs or drugs in development (Supplementary Table 19 ). Of note, the muscarinic acetylcholine receptor M3, encoded by CHRM3, is a well-characterized drug target for which many approved drugs exist, including for the treatment of asthma and obstructive lung disease. SLC6A4 encodes a serotonin transporter, a target for a number of drugs approved for treating depression and anxiety disorders, one of which (nortriptyline hydrochloride) has been trialed for use in inflammatory skin disorders (psoriasis and eczema); HTR4, which encodes a serotonin receptor, was identified in one of the earliest lung function Protective genetic variants that reduce the function or expression of a target protein could be mimicked by drugs and so are of particular interest. The minor allele (minor allele frequency (MAF) = 17%) at the new signal in an intron of FAM13A was associated with decreased expression of FAM13A in lung tissue and reduced risk of COPD. This, together with recent evidence from a study of the Fam13a knockout mouse 33 , suggests that pharmacological inhibition of FAM13A may be protective.
Extending our pathway analyses to all 234 genes implicated by gene expression or deleterious variants, we observed enrichment of genes related to 'signaling events mediated by the Hedgehog family' pathway. Hedgehog signaling has a crucial role in early development. Three members of this pathway, PTCH1, TGFB2 and HHIP, have previously been reported as likely causal genes underlying lung function association signals 34 . In this study, we additionally report PTHLH, encoding a parathyroid-hormone-like hormone, and CDON¸ encoding a Hedgehog co-receptor, as likely causal genes (the latter at a newly associated signal). Of the 73 well-imputed variants available in children, we show correlation (r = 0.62) of variant effect size estimates with those in adults. Should this pattern of correlation apply across all 97 lung-function-associated variants, this would suggest that many of these variants may act, at least in part, via effects on lung development. Elastic fiber pathways were overrepresented; products of elastin degradation have been shown to be elevated during acute exacerbations of COPD 35, 36 . In addition, degradation of elastin by excess neutrophil-released elastase in the lung leads to emphysema in individuals with α-1 antitrypsin deficiency. CARD9, another high-priority gene at a new signal, encodes an adaptor protein involved in neutrophil recruitment in respiratory fungal infection 37 . Tissue-specific enrichment of lung function signals overlapping H3K4me1 was seen in stomach smooth muscle. Although comparable H3K4me1 data were not available for airway smooth muscle, similar findings have been reported previously for rectal smooth muscle 38 .
The 17q21.31 inversion has previously been associated with lung function. Custom imputation of additional structural variation at the locus, along with eQTL evidence and deleterious variants in the gene, suggested that KANSL1 might drive the association. Among the new signals reported in this study, SNPs in an intron of EEFSEC on chromosome 3 are correlated with expression of nearby gene RUVBL1. Both KANSL1 and RUVBL1 encode members of histone modification complexes.
A new signal on chromosome 20 (rs72448466, intronic in ZGPAT), which showed association with FVC almost as strong as its association with FEV 1 , is an eQTL for the telomere gene RTEL1. Although rs72448466[->GT] was not the strongest eQTL for RTEL1 (r 2 = 0.6 with the top eQTL variant), RTEL1 is of interest as it has recently been implicated in familial pulmonary fibrosis 39 . Variant rs72448466 has also been associated with inflammatory bowel disease, prostate cancer and atopic dermatitis.
Our implication of genes of potential functional relevance to the 97 signals was based on gene expression data (eQTL) and associated deleterious variants within a gene. Although eQTL evidence currently gives the best in silico indication of which gene (or genes) might be functionally relevant to a signal, conclusive evidence for a causal relationship between SNP genotype and gene expression can only be obtained through direct molecular experiments.
Six signals of association have previously been identified within the HLA region. Using a custom imputation approach, we identified the presence of alanine (compared to aspartic acid, valine or serine) at amino acid position 57 in HLA-DQβ1 as associated with decreased lung function and the main driver of signals in this region. The presence of alanine is also strongly associated with risk of type 1 diabetes 40 .
The three lung function traits we studied are correlated. The overall and genetic correlations were as follows: 0.88 and 0.87 between FEV 1 and FVC; 0.46 versus 0.35 between FEV 1 and FEV 1 /FVC; and 0.038 and -0.17 between FVC and FEV 1 /FVC (transformed traits, as studied in UK Biobank and SpiroMeta 15 , respectively). One might expect variants showing the strongest association with FEV 1 and FEV 1 /FVC to be of the greatest relevance for COPD, and genetic correlations of -0.76 and -0.9 have been reported between COPD and FEV 1 and between COPD and FEV 1 /FVC, respectively 41 . We show, however, that variants associated with one of these traits also tend to be associated with one of the other two lung function traits studied (for example, all but two signals for FVC are also associated (P < 0.05) with FEV 1 ; Supplementary Table 4) . Although classification of COPD in UK Biobank was based on pre-bronchodilator spirometry data, we have previously shown that this leads to minimal misclassification of moderate-to-severe (GOLD score 2-4) COPD 42 . The effect size estimates for COPD associations could be influenced by differences in case ascertainment between the follow-up studies. Motivated by avoidance of potential winner's curse bias for the 48 variants discovered using UK BiLEVE, we excluded UK BiLEVE from individual variant analyses. However, this excluded 9,563 moderate-to-severe COPD cases, and the significance of COPD association tests for these variants should therefore be interpreted with caution. Notably, we found effect size estimates only slightly smaller in deeply characterized COPD case-control studies than in UK Biobank (OR per 1 s.d. change in allelic risk score = 1.36 as compared to 1.42). While we show that an appreciable proportion of COPD cases could be attributable to allelic risk scores above the first decile, great caution must be exercised in interpretation of population attributable risk fraction estimates, given considerations of shared etiologic responsibility 43 . The lung-function-associated variants we report were not associated with acute exacerbations of COPD. Although more powerful studies of exacerbations will be required, this suggests that different genetic mechanisms could underlie risk of acute exacerbations.
A threshold of P < 5 × 10 −8 is a valid threshold for genome-wide significance in GWAS analyses of common variants 44 . Our genotyping and imputation strategy resulted in testing of 27.6 million variants, of which 21.6 million had MAF <5% and 18.2 million had MAF <1%. Although all of our 43 signals were common, had we adopted a stricter threshold for genome-wide significance, for example, P < 1 × 10 −8 (recommended in a recent report of significance thresholds in wholegenome sequencing 44 ), only two of our signals (rs10246303[A>T] in the 3′ UTR of C1GALT1 on chromosome 7 and rs1698268[A>T] near LINC00911 on chromosome 14) would not have reached significance. Thirty-nine of the 43 signals were additionally supported by statistically significant independent replication in stage 2 (P < 0.05/43; Supplementary Table 3) .
In summary, our study provides comprehensive evidence regarding genetic variants associated with lung function and their association with susceptibility to COPD, with a more than threefold difference in COPD risk between the highest and lowest allelic risk score deciles.
While translation of GWAS findings can take some years and requires extensive additional work, selecting genetically supported targets could double the drug development success rate 17 . The future clinical relevance of our findings include contributions toward understanding of disease pathogenesis, identification of drug targets for targeting or repositioning of drugs 18 , and potentially improved prediction of COPD or its subtypes.
URLs. UK Biobank genetic data release, http://www.ukbiobank.ac.uk/ scientists-3/genetic-data/; LD score regression, Broad Institute, http:// ldsc.broadinstitute.org/; Global Initiative for Chronic Obstructive Lung Disease (GOLD), http://goldcopd.org/.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. using pooled single-SNP results, as described in Dastani et al. 51 , and weights were obtained using estimated effect sizes from either SpiroMeta 15 summary data (for SNPs discovered in UK Biobank) or from UK Biobank (for SNPs discovered elsewhere). The risk score was tested for the three lung function traits: FEV 1 , FVC and FEV 1 /FVC.
Refinement of signals.
A Bayesian method 52 was used to fine-map lung-function-associated signals to the set of variants that were 95% likely to contain the underlying causal variant (assuming that the causal variant has been analyzed). This was undertaken for new signals and for previously reported signals that reached P < 1 × 10 −5 in the stage 1 results. Following van de Bunt et al. 53 , we set the value of the prior W as 0.4 in the approximate Bayes factor formula. Signals in the HLA region were not included.
We re-imputed our 48,943 discovery samples across the HLA region (chr. 6: 29,607,078-33,267,103 (Build 37)) using IMPUTE2 v2.3.1 with a reference panel incorporating classical HLA alleles and amino acid changes 54 . The reference panel contained haplotypes for 5,225 samples from the Type 1 Diabetes Genetics Consortium (T1DGC) across 8,961 biallelic variants comprising 5,863 directly genotyped biallelic SNPs and 3,098 surrogate biallelic variants encoding multiallelic SNPs, indels, classical HLA alleles and amino acid changes. Association testing was then undertaken as described for stage 1 for Clinical relevance: COPD susceptibility and risk of COPD exacerbations in European and Chinese populations. The effect on COPD susceptibility of up to 95 of the 97 lung-function-associated signals was tested in the COPD study at deCODE Genetics (deCODE COPD study; 1,964 COPD cases and 142,262 controls for single-variant analyses and 1,248 COPD cases and 74,700 controls for risk score analyses); in three lung resection studies-Groningen, Laval and UBC (310 COPD cases and 332 controls); in COPD case-control studiesthe COPDGene Study (2,812 COPD cases and 2,534 controls), Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points (ECLIPSE; 1,736 COPD cases and 176 controls), the National Emphysema Treatment Trial (NETT) and the Normative Aging Study (NAS) (NETT/NAS; 376 COPD cases and 435 controls) and the Norway GenKOLS study (Genetics of Chronic Obstructive Lung Disease; 854 cases and 805 controls); in eMR studies-Mount Sinai BioMe Biobank (BioMe; 207 COPD cases and 1,817 controls) and the Geisinger-Regeneron DiscovEHR Study (DiscovEHR; 1,280 COPD cases and 13,321 controls for single-variant analyses and 1,264 COPD cases and 13,032 controls for risk score analyses); and in UK Biobank (not including UK BiLEVE samples; 984 cases and 26,561 controls in total) and UK BiLEVE (9,563 moderate-to-severe cases and 27,387 controls). rs7050036, located on chromosome X, and chr12:114743533, with MAF = 0.15%, were not present in most studies and were therefore excluded from these analyses, bringing the 97 signals to 95. Of the 95 signals, 47 were previously discovered independently of UK BiLEVE and were tested for association using all available COPD cases and controls (20,086 COPD cases and 215,630 controls). The remaining 48 signals were discovered using UK BiLEVE data and so were tested for association using 10,523 COPD cases and 188,243 controls (UK BiLEVE excluded). The effect on risk of COPD exacerbation was additionally tested in the Lung Health Study (LHS; 100 COPD exacerbation cases and 4,002 COPD controls) as well as subsets of UK Biobank (including UK BiLEVE; 647 cases and 9,900 controls), COPDGene (557 cases and 2,255 controls), ECLIPSE (278 cases and 1,458 controls), NETT/NAS (87 cases and 277 controls), GenKOLS (120 cases and 734 controls), BioMe (8 cases and 199 controls) and DiscovEHR (774 cases and 472 controls). Analyses of the effect of lung-function-associated variants on COPD susceptibility and on risk of COPD exacerbation in a Chineseancestry population were undertaken using the China Kadoorie Biobank (CKB) prospective cohort, in which data were available for 71 (single-variant analyses) or 70 (risk score analyses) of the 95 variants (or proxies) for analyses of COPD susceptibility (7,116 COPD cases and 20,919 controls) and risk of COPD exacerbation (5,292 cases and 1,824 controls). Further details on all studies, including case and control definitions, are given in the Supplementary Note and Supplementary Table 20 .
To test single-variant associations with COPD susceptibility and risk of exacerbation, logistic regression was applied using age, age 2 , sex and height as covariates (unless otherwise indicated; Supplementary Note) and assuming an additive genetic effect. To test the joint effect of these variants, risk alleles for the subset of the 95 signals with data available in each study (from 86 to 95) were summed to create an unweighted genetic risk score and logistic regression was used to test the effect of the risk score, as a continuous variable, on COPD status and COPD exacerbation status (adjusted for age, age 2 , sex and height, unless otherwise indicated; Supplementary Note). Results, both from singlevariant and risk score analyses, were subjected to meta-analysis separately for studies where similar study designs and phenotyping were used-eMR, case-control and lung resection studies-and results were also subjected to meta-analysis across studies. Inverse-variance-weighted meta-analysis was used. In CKB, analyses were adjusted for sex, age, age 2 , height, region (n = 10) and disease status (n = 5) and final results were genomic control corrected on the basis of genome-wide inflation estimates. Heterogeneity was evaluated using the I 2 statistic 57 .
We calculated odds ratios for spirometrically defined COPD for weighted risk score deciles in UK Biobank (incorporating UK BiLEVE; 10,547 cases (prebronchodilator percent predicted FEV 1 <80% and FEV 1 /FVC <0.7) and 53,948 controls (FEV 1 /FVC >0.7 and percent predicted FEV 1 >80%)). Weighting of the risk score was undertaken using log-transformed odds ratios for COPD calculated in studies free of winner's curse bias (Supplementary Table 21) . We scaled the log-transformed odds ratios so that the weights added up to 95.
Population attributable risk fraction calculation. The population attributable risk fraction (PARF) was calculated using the formula
where P(E) is the probability of the exposure, in this case the probability of having more risk alleles than individuals in the lowest decile of the risk score distribution (P(E) = 0.9), and OR refers to the odds of having COPD for individuals in deciles 2-10 of the risk score distribution as compared to the odds of having COPD for individuals in the lowest decile (decile 1) of the risk score distribution. The odds ratios were calculated separately in ever and heavy smokers using logistic regression adjusted for age, age 2 , sex, height and the first ten ancestry principal components and an additional pack-years adjustment for heavy smokers, and meta-analysis was then performed using inverse variance weighting. Confidence intervals were estimated using the formula above with the lower and upper bounds of the meta-analysis odds ratios estimated by logistic regression. These analyses were performed using UK Biobank data and the COPD case definition described above: individuals with percent predicted FEV 1 <80% and FEV 1 /FVC <0.7 were selected as COPD cases, and those with FEV 1 /FVC >0.7 and percent predicted FEV 1 >80% were selected as controls.
Implication of causal genes. To implicate the likely causal gene (or genes) for each of the new and previously reported signals (97 in total), we employed functional annotation and analysis of gene expression data. All variants within 25 kb of the top SNP at each locus, variants within 500 kb of the top SNP with r 2 >0.5, and variants within 1 Mb of the top SNP with r 2 >0.8 were annotated using the Ensembl Variant Effect Predictor (VEP). A variant was labeled as deleterious if it was a missense coding variant that was annotated as 'deleterious' by SIFT, was annotated as 'probably damaging' or 'potentially damaging' by PolyPhen-2, had a CADD scaled score ≥20 (CADD_PHRED ≥20) or had a GWAVA score >0.5. Deleterious variants were each, in turn, included as a covariate in the association analysis for the top SNP. If inclusion of the deleterious variant as a covariate reduced the association signal for the top SNP such that P > 0.01, that deleterious variant was deemed to explain part of the signal.
If annotation (for example, as a coding variant) implicated a specific gene, then the gene was classified as a high-priority gene for the relevant signal. At each signal, the sentinel SNP and top proxies with r 2 >0.4 and within 2 Mb (no limit on the number of proxies) were used to query three eQTL resources: lung eQTLs [23] [24] [25] , blood eQTLs 58 and GTEx 59 (artery (aorta and tibia), adrenal gland, colon sigmoid, esophagus (gastroesophageal junction and mucosa), transformed fibroblasts, lung, spleen, skin (sun-exposed lower leg), stomach, testis, thyroid, whole blood). An FDR of 10% was used as a threshold for significance in the lung and blood eQTL data sets, and an FDR threshold of 5% was used in GTEx (because of the large number of different tissues and cell types and the small sample size). A gene was classified as a potential causal gene if the sentinel SNP or proxy (r 2 >0.4) showed significant evidence of being an eQTL signal for that gene. Genes were further classified as high-priority genes if the variant most strongly associated with the lung function traits (or a proxy with r 2 >0.9) was also the variant most strongly associated with expression of the gene in one or more of the eQTL data sets (that is, there was colocalization of the lung-function-associated SNP and the gene-expression-associated SNP). Because of the extended LD across the MHC region, only high-priority genes were identified for the signals in the MHC region.
Pathway analyses. The genes implicated for each signal (high-priority genes only and all genes) were tested for enrichment of gene sets and pathways using ConsensusPathDB 60 . Pathways or gene sets represented entirely by genes implicated by the same association signal were excluded. Pathways or gene sets represented by two or more genes from the same association signal were flagged. Pathway enrichment using all genome-wide P values was undertaken using MAGENTA 61 as previously described 15 . Gene sets and pathways with FDR < 5% either including or excluding the HLA region are reported.
Tissue-specific enrichment of overlap with histone marks. Two methods were used to test for enrichment of the 97 signals of association with lung function for H3K4me1 and H3K4me3 histone marks in up to 127 different tissue and cell types from the Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenomics projects 38 .
First, enrichment was investigated with a hypergeometric test (as previously described 38 ) using SNPs from the GWAS Catalog (hg19; downloaded 2 November 2015) as background. The GWAS Catalog was pruned within each contributing GWAS to retain only SNPs that were at least 1 Mb apart in that study, resulting in 18,202 SNPs for further analysis. BEDtools was used to calculate overlap with precomputed 'gapped peaks' for H3K4me1 and H3K4me3 histone marks, and a hypergeometric test was used to test the significance of enrichment for the 97 lung function variants as compared to the background of GWAS Catalog SNPs. Control for multiple testing was undertaken by selecting 97 random variants from the pruned GWAS Catalog and repeating the enrichment computation. FDR was calculated from 10,000 randomizations, and FDR = 10% was used as the significance threshold.
The second method used, GoShifter, calculates overlap enrichment against a null distribution generated by locally shifting annotations 62 . LD was calculated using the stage 1 population. Precomputed 'narrow peaks' for H3K4me1 and
